Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12N2.ClH |
| Molecular Weight | 244.719 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(C1=NC2=C(N1)C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=CJTQARUHALKPGG-UHFFFAOYSA-N
InChI=1S/C14H12N2.ClH/c1-2-6-11(7-3-1)10-14-15-12-8-4-5-9-13(12)16-14;/h1-9H,10H2,(H,15,16);1H
| Molecular Formula | C14H12N2 |
| Molecular Weight | 208.2585 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.vidal.ru/drugs/bendazol
Sources: https://www.vidal.ru/drugs/bendazol
Bendazol (or dibazol), a vasodilator that used in Russia. This drug is indicated for the treatment of arterial hypertension, hypertensive crisis, spasms of internal organs (stomach ulcer, intestinal spasms), and diseases of the nervous system: residual effects of poliomyelitis. Bendazol lowers blood pressure by reducing cardiac output and expansion of peripheral vessels.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bis[1,3-bis-(1-benzyl-1H-benzimidazol-2-yl)-2-oxapropane]zinc(II) dipicrate dimethyl-formamide disolvate. | 2009-06-17 |
|
| 1,3-Bis(1-benzyl-1H-benzimidazol-2-yl)-2-oxapropane. | 2009-04-10 |
|
| Substituent effects on enthalpies of formation of nitrogen heterocycles: 2-substituted benzimidazoles and related compounds. | 2006-02-23 |
|
| Bis(2-benzyl-1H-benzimidazole-N3)dichlorozinc(II). | 2001-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.vidal.ru/drugs/bendazol
peripheral facial nerve palsy, polyneuritis.
hypertensive crisis – intravenous or intramuscular: 30-40 mg.
arterial hypertension with a significant increase in blood pressure – intramuscular: 20-30 mg 2-3 times / day, the course: 8-14 days.
nervous diseases: adults: 5 mg 1 time/day
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:51:58 GMT 2025
by
admin
on
Mon Mar 31 20:51:58 GMT 2025
|
| Record UNII |
ME751TL810
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m67
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID30153179
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
1212-48-2
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
214-921-2
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
ME751TL810
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
164798
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
SUB32247
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY | |||
|
100000124523
Created by
admin on Mon Mar 31 20:51:58 GMT 2025 , Edited by admin on Mon Mar 31 20:51:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |